Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

ated 8 to 10 percent of patients with long lesions. BSC plans to launch the product in the United States in August 2009. In May 2009, we announced that our partner BSC, had received approval from the FDA to market its TAXUS(R) Liberte(R) Atom(TM) paclitaxel-eluting coronary stent system, a next-generation paclitaxel-eluting stent specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS Express Atom(TM) stent as the only drug-eluting stents ("DES") approved for small vessel use in the United States.

In May 2009, we announced that our partner BSC had launched the platinum chromium TAXUS Element(TM) paclitaxel-eluting coronary stent system in select markets worldwide. The platinum chromium TAXUS Element paclitaxel-eluting coronary stent system is the third-generation BSC coronary stent platform that incorporates our research, technology and intellectual property related to the use of paclitaxel. The TAXUS Element stent features BSC's proprietary platinum chromium alloy, which is designed to enable thinner stent struts, increased flexibility and a lower stent profile while improving radial strength, recoil and radiopacity. In addition, the TAXUS Element stent platform incorporates new balloon technology intended to improve upon BSC's market-leading Maverick(R) balloon catheter technology.

New Independent TAXUS Clinical Data. In May 2009 we announced that our partner BSC had welcomed the publication of an article in the Journal of the American College of Cardiology (JACC) reviewing data on more than 19,000 patients from the Swedish national registry who were evaluated for restenosis, or the re-narrowing or arteries, after percutaneous coronary intervention ("PCI"). The Swedish Coronary Angiography and Angioplasty Registry holds data on all patients undergoing PCI in Sweden. The objective of this independent study was to evaluate restenosis rates of DES's in p
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
(Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Sept. 15 Epeius Biotechnologies,Corporation today announced that ... has been highlighted in a recent NEWS article,published ... (JNCI, Sept. 9,2008). The article, authored by Vickie ... medicine that may succeed where small,molecules and proteins ...
... Enobia Pharma, an emerging biotech,company focused ... presented pre-clinical data demonstrating that its enzyme,replacement ... bones that,have already been severely weakened by ... with Enobia,s product ENB-0040, significantly,increases survival and ...
... Offers Industry Dialogue, Commentary and How-To, ... Collaboration, PALO ALTO, Calif., Sept. 15 ... strategist and communicator, has,launched a new website, ... and communicators can share thinking, gain insights and,connect ...
Cached Biology Technology:Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 3
(Date:8/20/2014)... Multiple fires are visible in in this image of ... Many of these were most likely intentionally set in ... of a forest or stand of trees where the ... of deforestation include conversion of forestland to farms, ranches, ... the dark green of the Amazon Rainforest in the ...
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... found that new disease pathways involving more than one ... rare genetic disorder in which fatty substances called glycosphingolipids ... pain, and increased risk of cancer and Parkinson,s disease. ... expensive and more effective ways to treat the disorder, ...
... release is available in French . , Scientists ... McGill University have discovered that our brains have the ability ... specially-coded sounds, without any visual or tactile input. Not only ... the brain and how it perceives the world around us, ...
... Inhaling nitric oxide appears to safely and effectively ... researchers report., A study of 18 patients in Atlanta, ... oxide for four hours had better pain control than ... C. Alvin Head, chairman of the Department of Anesthesiology ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2See no shape, touch no shape, hear a shape? 2Inhaling nitric oxide eases pain crises in sickle cell patients 2
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
Biology Products: